Cargando…

Predicting changes in the pharmacokinetics of CYP3A‐metabolized drugs in hepatic impairment and insights into factors driving these changes

Physiologically based pharmacokinetic models, populated with drug‐metabolizing enzyme and transporter (DMET) abundance, can be used to predict the impact of hepatic impairment (HI) on the pharmacokinetics (PK) of drugs. To increase confidence in the predictive power of such models, they must be vali...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ladumor, Mayur K., Storelli, Flavia, Liang, Xiaomin, Lai, Yurong, Enogieru, Osatohanmwen J., Chothe, Paresh P., Evers, Raymond, Unadkat, Jashvant D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931433/ https://www.ncbi.nlm.nih.gov/pubmed/36540952 http://dx.doi.org/10.1002/psp4.12901

Ejemplares similares

Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model
por: Peng, Jinfu, et al.
Publicado: (2022)

Successful Prediction of Human Steady‐State Unbound Brain‐to‐Plasma Concentration Ratio of P‐gp Substrates Using the Proteomics‐Informed Relative Expression Factor Approach
por: Storelli, Flavia, et al.
Publicado: (2021)

Successful Prediction of Human Fetal Exposure to P-Glycoprotein Substrate Drugs Using the Proteomics-Informed Relative Expression Factor Approach and PBPK Modeling and Simulation
por: Anoshchenko, Olena, et al.
Publicado: (2021)

Physiologically‐Based Pharmacokinetic Modeling for the Prediction of CYP2D6‐Mediated Gene–Drug–Drug Interactions
por: Storelli, Flavia, et al.
Publicado: (2019)

Neural production of kynurenic acid in Caenorhabditis elegans requires the AAT-1 transporter
por: Lin, Lin, et al.
Publicado: (2020)

Comparison of Heavy Labeled (SIL) Peptide versus SILAC Protein Internal Standards for LC-MS/MS Quantification of Hepatic Drug Transporters
por: Prasad, Bhagwat, et al.
Publicado: (2014)

Contribution of Uptake and Efflux Transporters to Oral Pharmacokinetics of Furosemide
por: Chapa, Revathi, et al.
Publicado: (2020)

Estimating fetal exposure to the P‐gp substrates, corticosteroids, by PBPK modeling to inform prevention of neonatal respiratory distress syndrome
por: Anoshchenko, Olena, et al.
Publicado: (2021)

Adapting regulatory drug‐drug interaction guidance to design clinical pharmacokinetic natural product‐drug interaction studies: A NaPDI Center recommended approach
por: Cox, Emily J., et al.
Publicado: (2021)

The Effects of Genetic Mutations and Drugs on the Activity of the Thiamine Transporter, SLC19A2
por: Enogieru, Osatohanmwen J., et al.
Publicado: (2021)

Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial
por: Zamarripa, C. Austin, et al.
Publicado: (2023)

Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?
por: Yamazaki, Shinji, et al.
Publicado: (2022)

Inhibitory Effects of Baicalin on the Expression and Activity of CYP3A Induce the Pharmacokinetic Changes of Midazolam in Rats
por: Tian, Xin, et al.
Publicado: (2013)

Drugs in COVID‐19 Clinical Trials: Predicting Transporter‐Mediated Drug‐Drug Interactions Using In Vitro Assays and Real‐World Data
por: Yee, Sook Wah, et al.
Publicado: (2021)

A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction
por: Ke, A B, et al.
Publicado: (2012)

Evaluation of Pupillometry for CYP2D6 Phenotyping in Children Treated with Tramadol
por: Rodieux, Frédérique, et al.
Publicado: (2023)

A Semi-Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics
por: Quinney, S K, et al.
Publicado: (2012)

Changes in CYP3A4 Enzyme Expression and Biochemical Markers Under Acute Hypoxia Affect the Pharmacokinetics of Sildenafil
por: Zhang, Juanhong, et al.
Publicado: (2022)

Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach
por: Kneller, Lisa Alina, et al.
Publicado: (2020)

Gestational Age–Dependent Abundance of Human Placental Transporters as Determined by Quantitative Targeted Proteomics
por: Anoshchenko, Olena, et al.
Publicado: (2020)

Application of a PBPK model to elucidate the changes of systemic and liver exposures for rosuvastatin, carotegrast, and bromfenac followed by OATP inhibition in monkeys
por: Cheng, Yaofeng, et al.
Publicado: (2021)

In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects
por: Li, Yan, et al.
Publicado: (2018)

Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment
por: Watanabe, Akiko, et al.
Publicado: (2021)

Contribution of Baicalin on the Plasma Protein Binding Displacement and CYP3A Activity Inhibition to the Pharmacokinetic Changes of Nifedipine in Rats In Vivo and In Vitro
por: Cheng, Zhen-Yu, et al.
Publicado: (2014)

Rapid genomic changes by mineralotropic hormones and kinase SIK inhibition drive coordinated renal Cyp27b1 and Cyp24a1 expression via CREB modules
por: Meyer, Mark B., et al.
Publicado: (2022)

Physiologic and pharmacokinetic changes in pregnancy
por: Costantine, Maged M.
Publicado: (2014)

Driving Technical Change
por: Ryan, Terrence
Publicado: (2010)

Driving Climate Change
por: Sperling, Daniel, et al.
Publicado: (2010)

A repository of protein abundance data of drug metabolizing enzymes and transporters for applications in physiologically based pharmacokinetic (PBPK) modelling and simulation
por: Ladumor, Mayur K., et al.
Publicado: (2019)

Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics
por: Cheeti, Sravanthi, et al.
Publicado: (2020)

Mechanisms of Obesity-Induced Changes in Pharmacokinetics of IgG in Rats
por: Gao, Xizhe, et al.
Publicado: (2023)

The Impact of Inflammation on the In Vivo Activity of the Renal Transporters OAT1/3 in Pregnant Women Diagnosed with Acute Pyelonephritis
por: Benzi, Jhohann Richard de Lima, et al.
Publicado: (2023)

Changes in Alprazolam Metabolism by CYP3A43 Mutants
por: Zhao, Jie, et al.
Publicado: (2022)

Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
por: Saiz-Rodríguez, Miriam, et al.
Publicado: (2020)

Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter Quetiapine Pharmacokinetics
por: Zubiaur, Pablo, et al.
Publicado: (2021)

Potential Role of Patients’ CYP3A-Status in Clozapine Pharmacokinetics
por: Tóth, Katalin, et al.
Publicado: (2017)

Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition
por: Eisenmann, Eric D., et al.
Publicado: (2021)

Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug–Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
por: Fuhr, Laura Maria, et al.
Publicado: (2021)

A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles
por: Chung, Hyewon, et al.
Publicado: (2015)

Changes in human footprint drive changes in species extinction risk
por: Di Marco, Moreno, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5to3s6r0dpj1fo802snhql1qe2